Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of isatuximab in relapsed/refractory CD38-positive T-cell acute lymphoblastic leukemia
2023-507899-47-00Phase 2Authorised
- Sponsor
- Goethe University Frankfurt
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isatuximab in t-cell acute lymphoblastic leukemia (T-ALL), sponsored by Goethe University Frankfurt. Primary endpoints: Complete hematologic response after 2 induction cycles, Adverse events and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
isatuximab
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on 2023-507899-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507899-47-00.